Dissecting human ILC heterogeneity: more than just three subsets

Immunology

Volumn 153, Issue 3, 2018, Pages 297-303

  Simoni, Yannick ^a   Newell, Evan W ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

heterogeneity; human; ieILC1; ILC1; ILC2; ILC3

Indexed keywords

RECEPTOR; CYTOKINE;

CELL ACTIVATION; CELL HETEROGENEITY; CELL POPULATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; HUMAN; HUMAN TISSUE; LYMPHOID CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; TH17 CELL; TH2 CELL; ANIMAL; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASM;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; LYMPHOCYTE SUBSETS; LYMPHOCYTES; NEOPLASMS;

EID: 85038925587     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12862     Document Type: Review

References (85)

1. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al. Innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145–9.
2. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457:722–5.
3. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008; 29:958–70.
4. Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517:293–301.
5. Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M et al. Interleukin-12 and -23 control plasticity of CD127(+) group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 2015; 43:146–60.
6. Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L et al. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol 2016; 17:626–35.
7. Ohne Y, Silver JS, Thompson-Snipes L, Collet MA, Blanck JP, Cantarel BL et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat Immunol 2016; 17:646–55.
8. Lim AI, Menegatti S, Bustamante J, Le Bourhis L, Allez M, Rogge L et al. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J Exp Med 2016; 213:569–83.
9. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity 2014; 41:354–65.
10. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity 2014; 41:366–74.
11. Ealey KN, Moro K, Koyasu S. Are ILC2s Jekyll and Hyde in airway inflammation? Immunol Rev 2017; 278:207–18.
12. Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol 2017; 17:665–78.
13. Vely F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M et al. Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 2016; 17:1291–9.
14. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009; 126:458–65.
15. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31:3121–7.
16. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013; 83:702–13.
17. Bjorkstrom NK, Ljunggren HG, Michaelsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol 2016; 16:310–20.
18. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005; 102:2886–91.
19. Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T et al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep 2016; 6:26157.
20. Montaldo E, Vacca P, Chiossone L, Croxatto D, Loiacono F, Martini S et al. Unique Eomes(+) NK cell subsets are present in uterus and decidua during early pregnancy. Front Immunol 2015; 6:646.
21. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 2013; 38:769–81.
22. Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013; 14:221–9.
23. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH et al. CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis. J Immunol 2016; 196:2051–62.
24. Newell EW, Cheng Y. Mass cytometry: blessed with the curse of dimensionality. Nat Immunol 2016; 17:890–5.
25. Simoni Y, Fehlings M, Kloverpris HN, McGovern N, Koo SL, Loh CY et al. Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity 2017; 46:148–61.
26. Bekiaris V, Sedy JR, Rossetti M, Spreafico R, Sharma S, Rhode-Kurnow A et al. Human CD4+CD3− innate-like T cells provide a source of TNF and lymphotoxin-alphabeta and are elevated in rheumatoid arthritis. J Immunol 2013; 191:4611–8.
27. Bjorklund AK, Forkel M, Picelli S, Konya V, Theorell J, Friberg D et al. The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing. Nat Immunol 2016; 17:451–60.
28. Bernink JH, Mjosberg J, Spits H. Human ILC1: to be or not to be. Immunity 2017; 46:756–7.
29. Roan F, Ziegler SF. Human group 1 innate lymphocytes are negative for surface CD3epsilon but express CD5. Immunity 2017; 46:758–9.
30. Simoni Y, Newell EW. Toward meaningful definitions of innate-lymphoid-cell subsets. Immunity 2017; 46:760–1.
31. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12:1055–62.
32. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463:540–4.
33. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367–70.
34. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009; 10:66–74.
35. Hoorweg K, Peters CP, Cornelissen F, Aparicio-Domingo P, Papazian N, Kazemier G et al. Functional differences between human NKp44(-) and NKp44(+) RORC(+) innate lymphoid cells. Front Immunol 2012; 3:72.
36. Killig M, Glatzer T, Romagnani C. Recognition strategies of group 3 innate lymphoid cells. Front Immunol 2014; 5:142.
37. Glatzer T, Killig M, Meisig J, Ommert I, Luetke-Eversloh M, Babic M et al. RORgammat(+) innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 2013; 38:1223–35.
38. Hepworth MR, Monticelli LA, Fung TC, Ziegler CG, Grunberg S, Sinha R et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 2013; 498:113–7.
39. Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J et al. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells. Science 2015; 348:1031–5.
40. Shikhagaie MM, Bjorklund AK, Mjosberg J, Erjefalt JS, Cornelissen AS, Ros XR et al. Neuropilin-1 is expressed on lymphoid tissue residing LTi-like group 3 innate lymphoid cells and associated with ectopic lymphoid aggregates. Cell Rep 2017; 18:1761–73.
41. Withers DR, Hepworth MR, Wang X, Mackley EC, Halford EE, Dutton EE et al. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med 2016; 22:319–23.
42. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell 2017; 168:1086–100.e10.
43. Zhong C, Cui K, Wilhelm C, Hu G, Mao K, Belkaid Y et al. Group 3 innate lymphoid cells continuously require the transcription factor GATA-3 after commitment. Nat Immunol 2015; 17:169–78.
44. Kiss EA, Diefenbach A. Role of the aryl hydrocarbon receptor in controlling maintenance and functional programs of RORgammat(+) innate lymphoid cells and intraepithelial lymphocytes. Front Immunol 2012; 3:124.
45. Juelke K, Romagnani C. Differentiation of human innate lymphoid cells (ILCs). Curr Opin Immunol 2016; 38:75–85.
46. Montaldo E, Teixeira-Alves LG, Glatzer T, Durek P, Stervbo U, Hamann W et al. Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells. Immunity 2014; 41:988–1000.
47. Renoux VM, Zriwil A, Peitzsch C, Michaelsson J, Friberg D, Soneji S et al. Identification of a human natural killer cell lineage-restricted progenitor in fetal and adult tissues. Immunity 2015; 43:394–407.
48. Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA et al. A progenitor cell expressing transcription factor RORgammat generates all human innate lymphoid cell subsets. Immunity 2016; 44:1140–50.
49. Kim HS, Jang JH, Lee MB, Jung ID, Kim YM, Park YM et al. A novel IL-10-producing innate lymphoid cells (ILC10) in a contact hypersensitivity mouse model. BMB Rep 2016; 49:293–6.
50. Wang S, Xia P, Chen Y, Qu Y, Xiong Z, Ye B et al. Regulatory innate lymphoid cells control innate intestinal inflammation. Cell 2017; 171:201–16.e18.
51. Salimi M, Xue L, Jolin H, Hardman C, Cousins DJ, McKenzie AN et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing Type 2 cytokine production. J Immunol 2016; 196:45–54.
52. Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V et al. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol 2014; 192:3805–15.
53. Vacca P, Montaldo E, Croxatto D, Loiacono F, Canegallo F, Venturini PL et al. Identification of diverse innate lymphoid cells in human decidua. Mucosal Immunol 2015; 8:254–64.
54. Kramer B, Goeser F, Lutz P, Glassner A, Boesecke C, Schwarze-Zander C et al. Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy. PLOS Pathog 2017; 13:e1006373.
55. Kloverpris HN, Kazer SW, Mjosberg J, Mabuka JM, Wellmann A, Ndhlovu Z et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity 2016; 44:391–405.
56. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013; 4:69.
57. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011; 108:728–32.
58. Campbell KS, Yusa S-i, Kikuchi-Maki A, Catina TL. NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 2004; 172:899–906.
59. Narni-Mancinelli E, Gauthier L, Baratin M, Guia S, Fenis A, Deghmane AE et al. Complement factor P is a ligand for the natural killer cell-activating receptor NKp46. Sci Immunol 2017; 2:eaam9628.
60. Bal SM, Bernink JH, Nagasawa M, Groot J, Shikhagaie MM, Golebski K et al. IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 2016; 17:636–45.
61. Paclik D, Stehle C, Lahmann A, Hutloff A, Romagnani C. ICOS regulates the pool of group 2 innate lymphoid cells under homeostatic and inflammatory conditions in mice. Eur J Immunol 2015; 45:2766–72.
62. Maazi H, Patel N, Sankaranarayanan I, Suzuki Y, Rigas D, Soroosh P et al. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity 2015; 42:538–51.
63. Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, Lazzari A et al. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-gamma contributes to modulate immune responses. J Biol Chem 2011; 286:37964–75.
64. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med 2017; 9:eaam9171.
65. Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep 2014; 9:1075–88.
66. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013; 4:289.
67. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, Park CS et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002; 168:1146–53.
68. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19:423–74.
69. Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124:700–9.
70. Wagner M, Moro K, Koyasu S. Plastic heterogeneity of innate lymphoid cells in cancer. Trends Cancer 2017; 3:326–35.
71. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012; 37:649–59.
72. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013; 210:2939–50.
73. Mauer J, Denson JL, Bruning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015; 36:92–101.
74. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448–57.
75. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012; 33:571–7.
76. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun 2015; 6:8280.
77. Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A 2010; 107:10961–6.
78. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371–81.
79. Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 2014; 133:1184–94.
80. Camelo A, Rosignoli G, Ohne Y, Stewart RA, Overed-Sayer C, Sleeman MA et al. IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells. Blood Adv 2017; 1:577–89.
81. Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. eLife 2016; 5:e10066.
82. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol 2016; 12:37–48.
83. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167–76.
84. Gury-BenAri M, Thaiss CA, Serafini N, Winter DR, Giladi A, Lara-Astiaso D et al. The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. Cell 2016; 166:1231–46.e13.
85. Ealey KN, Koyasu S. How many subsets of innate lymphoid cells do we need? Immunity 2017; 46:10–3.